09:20 AM EDT, 03/25/2024 (MT Newswires) -- Dyne Therapeutics ( DYN ) said Monday its President and Chief Executive Joshua Brumm has stepped down to pursue a career in healthcare investing, effective immediately.

The clinical-stage muscle disease company has named John Cox as Brumm's successor. Brumm will remain with the company as an advisor to help with the transition.

Cox was most recently CEO of Repertoire Immune Medicines and its predecessor from 2019 until 2022. He was also CEO of Biogen spin-off Bioverativ from 2017 to 2018 before it was acquired by Sanofi ( SNY ) .

Shares of Dyne Therapeutics ( DYN ) were down nearly 10% in recent premarket activity.

Price: 25.54, Change: -2.7, Percent Change: -9.56